Business news: Elsevier, FDA

Share this article:
Elsevier launched a new title: the Journal of Behavioral Sciences. The publication is the official journal of the Association for Contextual Behavioral Science. “It has been a long time in the making,” ACBS president-elect Sonja Batten said in a statement. The quarterly's first issue printed in December and is available on ScienceDirect.

FDA is looking into opioids and chronic pain and has scheduled a two-day public hearing, beginning February 7. Each seven-hour session will be held in Bethesda, MD, and will address questions that include what methods professionals currently use to distinguish types of pain, how they differentiate chronic from short-term pain and if there is data that would support or oppose implementing maximum daily doses. The drug category came under periodic scrutiny in 2012, a review which included the outing of an industry-funded pain-pill advocacy group for recommendations lacking scientific bases, as well as CDC research that indicates prescription painkillers, both opioid and non, are linked to 75% of prescription drug overdoses. The CDC also reports that about 2 million people first used prescription painkillers for nonmedical reasons in 2010. This comes down to approximately 5,500 first-time non-medical users a day. The FDA issued draft guidance earlier this month that proposes drug makers test a drug's abuse potential by evaluating the benefits of bypassing abuse-deterrent measures through crushing, grinding or melting the product or how a formulation could make extracting the opiates difficult and thereby limit its desirability for intravenous injection.
Share this article:

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.